1083MO Final results from ILLUMINATE-204, a phase I/II trial of intratumoral tilsotolimod in combination with ipilimumab in PD-1 inhibitor refractory advanced melanoma
Cara Haymaker, Robert H.I. Andtbacka, Douglas B. Johnson, M. Shaheen, S. Rahimian, S. Chunduru, Nashat Gabrail, Gary C. Doolittle, Igor Puzanov, Joseph Markowitz, Chantale Bernatchez, Adi Diab
Topics & Concepts
MedicineIpilimumabInternal medicineMelanomaResponse Evaluation Criteria in Solid TumorsOncologyRefractory (planetary science)Phases of clinical researchProgressive diseaseGastroenterologyCombination therapyCancerClinical trialImmunotherapyChemotherapyCancer researchAstrobiologyPhysicsCancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesCAR-T cell therapy research